Option chain shows key data for Provectus's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Provectus.

Provectus (OTC:PVCT) Stock, Option Chain

Provectus

Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (HXs). Its HX molecule is named rose bengal sodium. The Company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of its current clinical development programs and the preclinical formulations of its current drug discovery programs.

Penny Stocks

Short Ideas

PVCT

On Monday, shares of Provectus Biopharm (OTC: PVCT) experienced volatile short activity. After the activity, the stock price went up +7.53% to $0.14.

The overall sentiment for PVCT has been Bullish.

Short Volatility Alert: Provectus Biopharm

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group’s Most Active List In December

Small Cap

Markets

AERG

ATLX

CLNV

CYDY

DTEGY

ETHE

GBTC

GTBIF

HEINY

AMERICAN LITHIUM CORP ORD by American Lithium Corp.

LIACF

NBLD

OTCM

REII

RHHBY

WMMVY

ZURVY

On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate had jumped 25 basis points, 50 basis points and then 75 points four times in a row in between each Federal Reserve meeting.  

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group&#39;s Most Active List In December

News

Press Releases

Provectus Will Report Data on PV-10 in Combo Therapy, T-Cell Mediated Immunity at AACR Meeting

PROVECTUS BIOPHARMS by Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals Inc

<ul>
<li>Accelerates wound closure and improves wound healing &nbsp;</li>
</ul>
KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company") (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/PVCT#OTCQB">PVCT</a>) today announced that non-clinical data on Provectus's proprietary, pharmaceutical-grade, rose bengal sodium ("RBS") active pharmaceutical ingredient for the topical treatment of full-thickness cutaneous wounds were presented at the annual meeting of the Society for Investigative Dermatology ("SID"), held May 15-18, 2024 in Dallas, Texas.
This work is part of research being conducted by Amina El Ayadi, PhD, Assistant Professor, Surgical Sciences Division of the Burn, Trauma, and Critical Care Research Laboratory in the Department of Surgery at the University of Texas Medical Branch at Galveston ("UTMB").

Biotech

General

Provectus Biopharmaceuticals Presents Rose Bengal Sodium Presentation For Treatment Of Full-Thickness Cutaneous Wounds At SID 2024 Annual Meeting

On Monday, shares of Provectus Biopharm (OTC: <a class="ticker" href="https://www.benzinga.com/stock/pvct#OTC">PVCT</a>) experienced volatile short activity. After the activity, the stock price went up +7.53% to $0.14.
The overall sentiment for PVCT has been Bullish.
The signal from the volatility alert is trending Bearish. Therefore, the recommendation is to Increase Short Exposure.
The volatility alert was produced on the prior trading date, 1/23/2023 with a volatility change of +51.36%. The current volatility indicator stands at 5.086.
Overview: 
The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the purpose of providing liquidity to short sellers. When unusual activity occurs in the securities lending markets, it acts as an upstream indicator to what is likely to occur downstream in the regular stock market.
Understanding the Volatility Alert: 
Overall sentiment is considered &quot;bear&quot; when broad market activity of the stock has been shown to indicate a negative directional basis, or is considered &quot;bull&quot; when indicating a positive directional basis. The securities lending volatility indicator provides a signal when it detects unusual short activity. Unusual short activity is based off a computer generated algorithmic formula utilizing securities lending trade details such as the volume of shares being shorted, the rate being paid to short the shares, and the type of collateral being posted - amongst other variables. The current volatility is the respective trading day&#39;s calculated securities lending volatility value. The volatility percentage change is the percentage difference in volatility between the two most recent days. The recommendation is a suggestive strategy, inferred from the strength of the Signal Trending, Current Volatility, and Volatility % Change. Recommendations may include, &quot;Strong Buy&quot;, &quot;Strong Sell&quot;, &quot;Increase Short Exposure&quot;, &quot;Decrease Short Exposure&quot;, or &quot;Market Neutral&quot;.
ANY INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR IMPLY INVESTMENT ADVICE

On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate had jumped 25 basis points, 50 basis points and then 75 points four times in a row in between each Federal Reserve meeting.&nbsp;&nbsp;
In a summary of the Federal Open Market Committee (FOMC) meeting on January 4th, 2022, the committee indicated that &ldquo;A number of participants emphasized that it would be important to clearly communicate that a slowing in the pace of rate increases was not an indication of any weakening of the Committee&rsquo;s resolve to achieve its price-stability goal or a judgment that inflation was already on a persistent downward path.&rdquo;
In the meantime, OTC Markets Group Inc.&rsquo;s (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/otcm#OTCQX">OTCM</a>) markets reported a decline in total monthly volume compared to last month, recording $32.1 billion in December compared to the $36.3 billion in November. The regulated markets, however, saw a jump in trading volume in the OTCQB Venture Market.&nbsp;
<h3>A Dive Into The OTCQX Best Market&rsquo;s Most-Active List</h3>
The OTCQX Best Market recorded $5.1 billion in trading volume in December, a slight decrease from the $6.7 billion in trading volume in <a href="https://www.benzinga.com/markets/penny-stocks/22/12/30054783/otc-market-groups-most-active-list-in-november-a-dive-into-the-names-experiencing-volume-cha">November</a>.&nbsp;
The top three companies on OTCQX&rsquo;s Most-Active list experienced a slight reshuffle in December. Volume surged away from each of the top 3 contenders, but Roche Holding AG (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/rhhby#OTCQX">RHHBY</a>) claimed the top spot while crypto-centric securities Grayscale Bitcoin Trust (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/gbtc#OTCQX">GBTC</a>) and Grayscale Ethereum Trust (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/ethe#OTCQX">ETHE</a>) slotted in at 2nd and 3rd place.&nbsp;
The remaining constituents in OTCQX&rsquo;s top 10 Most-Active securities list experienced change in December, welcoming Green Thumb Industries Inc. (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/gtbif#OTCQX">GTBIF</a>), Trulieve Cannabis Corporation (OTCQX:&nbsp; TCNNF) and Heineken N.V. (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/heiny#OTCQX">HEINY</a>) in place of Deutsche Telekom AG (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/dtegy#OTCQX">DTEGY</a>), Computer Services Inc. and Zurich Insurance Group (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/zurvy#OTCQX">ZURVY</a>).
Computer Services was acquired and is no longer a publicly-listed company.&nbsp;
Other notable movers:
<ul>
<li>Wal-Mart De Mexico S.A.B. de C.V. (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/wmmvy#OTCQX">WMMVY</a>) claimed the 16th spot on OTCQX&rsquo;s Most Active list, experiencing a 207% increase in trading volume.</li>
</ul>
<h3>The OTCQB Venture Market: A &ldquo;Battle&rdquo; For Top 10</h3>
The OTCQB Venture Market recorded $689.4 million in trading volume in December, a slight increase from the $652.4 million in trading volume in November.&nbsp;
Like the OTCQX Best Market, the OTCQB Venture Market&rsquo;s top 10 Most Active list for the month saw new entries. Specifically, CytoDyn Inc. (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/cydy#OTCQB">CYDY</a>) reappears in the top 10 Most Active list, bouncing back from its drop-off in November. Additionally, Renewable Innovations, Inc. (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/reii#OTCQB">REII</a>) (formerly NESTBUILDER.COM CORP. (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/nbld#OTCQB">NBLD</a>)), a digital media and marketing services company, entered the top 10 Most Active list. The two displace Clean Vision Corporation (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/clnv#OTCQB">CLNV</a>) and Atlas Lithium Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atlx#NASDAQ">ATLX</a>), both of which were on the list in November.&nbsp;
Other notable movers include:
<ul>
<li>American Lithium Corp. (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/liacf#OTCQB">LIACF</a>), which climbed to 11th place on the Most Active list and recorded a $6.3 million rise in trading volume compared to last month.&nbsp;&nbsp;</li>
<li>Applied Energetics Inc. (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/aerg#OTCQB">AERG</a>), which climbed to 15th place on the Most Active list and recorded a $3.4 million rise in trading volume compared to last month.&nbsp;</li>
<li>Provectus Biopharmaceuticals, Inc. (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/pvct#OTCQB">PVCT</a>), which climbed to 28th place on the Most Active list and recorded a volume rise of $2.1 million compared to last month.&nbsp;</li>
</ul>
The OTCQX And OTCQB Top 10
Below are the top 10 most actively traded securities on the OTCQX Best Market and OTCQB Venture Market in December.&nbsp;
OTCQX Top 10:&nbsp;
<table>
<tbody>
<tr>
<td>
Company Name
</td>
<td>
Symbol
</td>
<td>
December Dollar Volume
</td>
</tr>
<tr>
<td>
Roche Holding Ltd.
</td>
<td>
<a href="http://www.otcmarkets.com/stock/RHHBY/quote">RHHBY</a>
</td>
<td>
$938,518,331
</td>
</tr>
<tr>
<td>
Grayscale Bitcoin Trust (BTC)
</td>
<td>
<a href="http://www.otcmarkets.com/stock/GBTC/quote">GBTC</a>
</td>
<td>
$695,292,404
</td>
</tr>
<tr>
<td>
Grayscale Ethereum Trust (ETH)
</td>
<td>
<a href="http://www.otcmarkets.com/stock/ETHE/quote">ETHE</a>
</td>
<td>
$314,257,520
</td>
</tr>
<tr>
<td>
adidas AG
</td>
<td>
<a href="http://www.otcmarkets.com/stock/ADDYY/quote">ADDYY</a>
</td>
<td>
$201,524,251
</td>
</tr>
<tr>
<td>
Green Thumb Industries Inc.
</td>
<td>
<a href="http://www.otcmarkets.com/stock/GTBIF/quote">GTBIF</a>
</td>
<td>
$181,456,135
</td>
</tr>
<tr>
<td>
Infineon Technologies AG&nbsp;
</td>
<td>
<a href="http://www.otcmarkets.com/stock/IFNNY/quote">IFNNY</a>
</td>
<td>
$170,922,774
</td>
</tr>
<tr>
<td>
Danone
</td>
<td>
<a href="http://www.otcmarkets.com/stock/DANOY/quote">DANOY</a>
</td>
<td>
$138,268,039
</td>
</tr>
<tr>
<td>
Trulieve Cannabis Corporation
</td>
<td>
<a href="http://www.otcmarkets.com/stock/TCNNF/quote">TCNNF</a>
</td>
<td>
$128,114,184
</td>
</tr>
<tr>
<td>
Heineken N.V.
</td>
<td>
HEINY
</td>
<td>
$114,035,029
</td>
</tr>
<tr>
<td>
BNP Paribas&nbsp;
</td>
<td>
<a href="http://www.otcmarkets.com/stock/BNPQY/quote">BNPQY</a>
</td>
<td>
$113,842,833
</td>
</tr>
</tbody>
</table>
OTCQB Top 10:&nbsp;&nbsp;
<table>
<tbody>
<tr>
<td>
Company Name
</td>
<td>
Symbol
</td>
<td>
December Dollar Volume
</td>
</tr>
<tr>
<td>
Vision Energy Corporation
</td>
<td>
VENG
</td>
<td>
$153,008,087
</td>
</tr>
<tr>
<td>
Northwest Biotherapeutics Inc.
</td>
<td>
<a href="http://www.otcmarkets.com/stock/NWBO/quote">NWBO</a>
</td>
<td>
$46,999,760
</td>
</tr>
<tr>
<td>
Global Tech Industries Group Inc.
</td>
<td>
<a href="http://www.otcmarkets.com/stock/GTII/quote">GTII</a>
</td>
<td>
$40,034,634
</td>
</tr>
<tr>
<td>
Fannie Mae&nbsp;
</td>
<td>
<a href="http://www.otcmarkets.com/stock/FNMA/quote">FNMA</a>
</td>
<td>
$21,525,480
</td>
</tr>
<tr>
<td>
CytoDyn Inc.
</td>
<td>
<a href="http://www.otcmarkets.com/stock/CYDY/quote">CYDY</a>
</td>
<td>
$16,512,030
</td>
</tr>
<tr>
<td>
Netlist Inc.
</td>
<td>
<a href="http://www.otcmarkets.com/stock/NLST/quote">NLST</a>
</td>
<td>
$16,467,857
</td>
</tr>
<tr>
<td>
Freddie Mac&nbsp;
</td>
<td>
<a href="https://www.otcmarkets.com/stock/FMCC/quote">FMCC</a>
</td>
<td>
$14,601,523
</td>
</tr>
<tr>
<td>
American Battery Technology Co.
</td>
<td>
<a href="http://www.otcmarkets.com/stock/ABML/quote">ABML</a>
</td>
<td>
$14,274,807
</td>
</tr>
<tr>
<td>
NESTBUILDER.COM CORP.
</td>
<td>
<a href="http://www.otcmarkets.com/stock/NBLD/quote">NBLD</a>
</td>
<td>
$11,538,861
</td>
</tr>
<tr>
<td>
CREATD INC.
</td>
<td>
<a href="http://www.otcmarkets.com/stock/CRTD/quote">CRTD</a>
</td>
<td>
$11,351,902
</td>
</tr>
</tbody>
</table>
Featured Photo by <a href="https://unsplash.com/@chrisliverani">Chris Liverani</a> on <a href="https://unsplash.com/photos/dBI_My696Rk">Unsplash</a>&nbsp;
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December

Events

ACET

ACLX

ADXS

BGNE

CGEM

GRTX

Several Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Meeting Jun. 3-7: Provectus, Advaxis, Adicet Bio, Cullinan Oncology, Galera, BeiGene, Arcellx, PDS Biotech, Tempest, Karyopharm

Intraday Update

Movers

Trading Ideas

AACAF

AACAY

AAGIY

AAIGF

AAMMF

AAUKF

AAVMY

AAVVF

ABBRF

ABCP

ABILF

ABMC

ABNAF

ABSSF

ACDVF

ACGBY

ARCH BIOPARTNERS INC ORD by Arch Biopartners Inc.

ACHFF

ACKRF

ACNDF

ACNNF

ACOPF

ACRL

ACSAY

ACUIF

ADAD

ADDDF

ADDYY

ADMT

ADYEY

AEGOF

AETUF

AEXAY

AFLYY

AGCBF

AGESY

AGFAF

AGGFF

AHCHY

AHEXY

ALTERNATE HEALTH CORP ORD by Alternate Health Corp.

AHGIF

AHKSF

AHKSY

AHWSF

AIBGY

AIBRF

AIQUY

AIRRF

AISSF

AJMPF

AJXGF

AKAOQ

AKBTY

AKZOY

ALBY

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALFVY

ALIAF

ALIF

Allianz Ag Muenchen Namen-Akt Vinkuliert Shares

ALIZF

ALLVF

ALMTF

ALPMY

ALSMY

ALVOF

ALYI

AMADY

AMAZ

AMBBY

AMIGY

AMKAF

AMKBF

AMKBY

AMLZF

AMMX

AMRQQ

AMXEF

ANEWF

ANGPY

ANPDF

ANPDY

ANSLY

ANTH

ANACONDA MINING INC by Anaconda Mining Inc.

ANXGF

Australia and New Zealand Banking Group Limited

ANZBY

ANZLY

AOIFF

AOMFF

ASCOT RESOURCES LTD by Ascot Resources Ltd.

AOTVF

APELY

APHD

APMCF

AQARF

ARAFF

ARESF

ARGKF

ARKAY

ARNGF

ARREF

ARRRF

Stocks That Hit 52-Week Highs On Tuesday

Offerings

Provectus Biopharmaceuticals Proposes "Best Efforts" Public Offering

Provectus Biopharmaceuticals, Inc. Announces Proposed Public Offering of Preferred Stock and Warrants

Legal

Provectus Biopharma Announces Patent For Rose Bengal Analogs

Provectus Biopharma Gets Patent For Halogenated Xanthenes

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, <a href="http://www.provectusbio.com" title="www.provectusbio.com">www.provectusbio.com</a>), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"), today announced that it has formed an Australian subsidiary, Provectus Biopharmaceuticals Australia Pty Ltd. In addition, the Company is opening a Sydney office in New South Wales. 
Peter Culpepper, Interim CEO, stated, "The creation of an Australian entity is a fundamental part of our plans for extended global reach in conjunction with planned partnering for commercialization of PV-10." 
He noted, "Provectus has already been very active in Australia for years because of our research into PV-10 as an investigational treatment for melanoma. In fact, we began our phase 1 study of PV-10 in 2005 at the Sydney Melanoma Unit in North Sydney and the Newcastle Melanoma Unit in Waratah, both in New South Wales. Since then, we have also worked with the Princess Alexandra Hospital in Brisbane, Queensland, the Royal Adelaide Hospital in Adelaide, South Australia, and the Peter MacCallum Cancer Centre in Melbourne, Victoria." 
Culpepper concluded, "With a subsidiary in Australia, we are bringing our corporate structure in line with our scientific work. Our research and development program has been international from the very beginning, and now, Provectus is an international company. The new unit should make it easier to work with the Australian regulatory authorities, and having an office in the region may facilitate our work in Asian markets as Sydney is just two hours ahead of Beijing, Hong Kong and Singapore. If and when PV-10 receives approval in Australia and other nations in the region, we will have pre-positioned ourselves to develop a sales and marketing force."

Provectus Biopharma Announces Austrailian Subsidiary Formed

Provectus Biopharmaceuticals, Inc. (NYSE MKT: <a class="ticker" href="/stock/pvct#NYSE MKT">PVCT</a>) today announced that data on PV-10 as a treatment for melanoma was presented June 30, 2016 at the 6th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany.

	 
	Sanjiv Agarwala, MD, Professor of Medicine at Temple University, Chief, Oncology &amp; Hematology at St. Luke&rsquo;s Cancer Center in Bethlehem, Pennsylvania and Global Lead Investigator for the phase 3 study of PV-10 in locally advanced cutaneous melanoma (protocol PV-10-MM-31), participated in a symposium, &ldquo;Current Clinical Trials I.&rdquo; His presentation covered the status of clinical trials of leading oncolytic agents for the treatment of soft tissue and skin metastases, including the ongoing phase 3 study of PV-10 and the phase 1b study of PV-10 in combination with pembrolizumab (Keytruda&reg;).

	 
	During his presentation, Dr. Agarwala noted that &ldquo;systemic therapy is not always possible or appropriate&rdquo; for patients with locally advanced disease, and that &ldquo;local-regional control of soft tissue/skin metastases is clinically important.&rdquo; Touching on six different types of oncolytic therapy, he highlighted key efficacy and safety data for PV-10 when used for direct ablation of dermal and soft tissue metastases, and noted that PV-10 is the only one currently being studied as both monotherapy and in the combination setting (with pembrolizumab). With regard to combination therapy, he noted that newer intralesional therapies like PV-10 are the &ldquo;backbone for future combinations&rdquo; since they are capable of producing a systemic anti-tumor immune response complementary to that of immune checkpoint inhibitors.

Provectus Biopharmaceuticals Announces PV-10 Data Discussed at 6th European Post-Chicago Melanoma/Skin Cancer Meeting

Provectus Biopharmaceuticals, Inc. (NYSE MKT: <a class="ticker" href="/stock/pvct#NYSE MKT">PVCT</a>) today announced that the European Society for Medical Oncology&#39;s Scientific Committee has accepted an abstract for a poster presentation detailing the use of PV-10 as a treatment for stage III and IV melanoma as part of ESMO&#39;s 2016 Congress.

	&nbsp;

	The exact date and time of the presentation, titled &quot;Intralesional Rose Bengal for Stage III and IV Melanoma,&quot; has yet to be decided. When the schedule is set, the details for this abstract, #3438, will be available at <a href="http://www.esmo.org/Conferences/ESMO-2016-Congress/Programme" title="http://www.esmo.org/Conferences/ESMO-2016-Congress/Programme">http://www.esmo.org/Conferences/ESMO-2016-Congress/Programme</a>.

	&nbsp;

	In addition, the abstract will also be published in the ESMO 2016 Congress Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. ESMO has not yet announced the final publication number. The ESMO 2016 Congress will be held in Copenhagen, Denmark, from October 7-11, 2016.

Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at ESMO 2016 Congress

On April 11, 2016, Provectus Biopharmaceuticals, Inc. (the "Company"), in its capacity as a nominal defendant, entered into a Stipulation of Settlement (the "Settlement") in the shareholder derivative action filed in the United States District Court, Eastern District of Tennessee, Knoxville Division (the "Court"), against H. Craig Dees, Timothy C. Scott, Jan E. Koe, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, the "Individual Defendants"), and against the Company as a nominal defendant (the "Shareholder Derivative Lawsuit"). In addition to the Company and the Individual Defendants, plaintiffs Karla Hurtado and Paul Montiminy are parties to the Settlement. The Settlement was filed with the Court on April 29, 2016. 
By entering into the Settlement, the settling parties have resolved the derivative claims to their mutual satisfaction. The Individual Defendants have not admitted the validity of any claims or allegations, and the settling plaintiffs have not admitted that any claims or allegations lack merit or foundation. Under the terms of the Settlement, the Company has agreed to implement certain corporate governance changes, including adopting a Disclosure Controls and Procedures Policy and using its best efforts to replace one of its existing directors with an independent, outside director by June 30, 2017. The Individual Defendants and the Company also agreed to pay from insurance proceeds $300,000 to plaintiffs' counsel, as an award of attorneys' fees and reimbursement of expenses in connection with their role in this litigation, subject to Court approval. The insurance carrier will pay the award directly to the plaintiffs' counsel's trust account, and the payment will not pass through the Company. 
The Settlement remains subject to approval by the Court and a settlement hearing. The hearing on the terms of the proposed Settlement will be held on August 26, 2016 at 10:00 a.m. Eastern Time to determine whether: (1) the terms and conditions of the Settlement are fair, reasonable and adequate and in the best interest of the Company and its stockholders, (2) the judgment, as provided for in the Settlement, should be entered, and (3) the request of plaintiffs' counsel for the $300,000 award of attorneys' fees and reimbursement of expenses should be approved. 
As required by the Court's Order Granting Preliminary Approval of Settlement,, the Notice of Pendency of Proposed Settlement of Shareholder Derivative Action is attached to this Current Report on Form 8-K as Exhibit 99.1.

Provectus Biopharmaceuticals Enters Stipulation Of Settlement In Shareholder Derivative Action

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, <a href="http://www.provectusbio.com" title="www.provectusbio.com">www.provectusbio.com</a>), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"), today announced that an article on the use of PV-10 for in-transit melanoma has been published by the Journal of Surgical Oncology. It expands on a presentation on the same topic given at the Royal Australasian College of Surgeons 85th Annual Scientific Congress, which was held 2-6 May 2016, in Brisbane, Australia. 
Titled "Intralesional PV-10 for In-Transit Melanoma - A Single Centre Experience," the article reports on use of PV-10 in the management of in-transit melanoma at the Peter MacCallum Cancer Centre, in East Melbourne, Victoria, Australia. The article was authored by Jocelyn Lippey et al. using retrospective analysis of data from nineteen patients receiving PV-10 at the center between 2010 and 2014. 
Dr. Lippey reported, "After a median follow up of 11.7 months, disease control was achieved in 63% of patients. Five patients (26%) achieved a complete response, another five (26%) patients achieved a partial response, and two patients had stable disease (11%) at the time of last follow-up. Seventy-four percent (14/19) of patients had a clinical response at time of first follow-up (median time 21 days); range 8–91 days. Younger patients and those with smaller lesions were more likely to respond to treatment." The median age of patients in this series was 80 years. 
Dr. Lippey also noted, "Ten patients did not have all lesions injected, primarily due to the number of lesions present. A bystander response was noted in un-injected lesions in 50% of patients who did not have all their lesions directly injected." 
Eric Wachter, CTO of Provectus commented, "The results reported here are consistent with other evaluations of PV-10 in melanoma, and highlight both the rapid ablative properties and the immunologic features of PV-10 as an investigational ablative immunotherapy." 
The article can be found at <a href="http://onlinelibrary.wiley.com/doi/10.1002/jso.24311/pdf" title="http://onlinelibrary.wiley.com/doi/10.1002/jso.24311/pdf">http://onlinelibrary.wiley.com/doi/10.1002/jso.24311/pdf</a>

Provectus Biopharmaceuticals Announces Publication of Article on PV-10 for In-Transit Melanoma in Journal of Surgical Oncology, Shows Disease Control Achieved In 63% Of Patients On 11.7 Month Follow Up

Provectus Biopharma Reports Abstract Available on PV-10 Plus Radiotherapy in Melanoma

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, <a href="http://www.pvct.com" title="www.pvct.com">www.pvct.com</a>), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"), announced today that researchers from Moffitt Cancer Center in Tampa, Florida, presented a poster titled, "T cell Mediated Immunity After Combination Therapy with Intralesional PV-10 and Co-Inhibitory Blockade in a Melanoma Model," at the American Association for Cancer Research (AACR) Annual Meeting 2016, held at the Ernest N. Morial Convention Center in New Orleans, Louisiana. 
In the poster, authors Amy M Weber, Hao Liu, Krithika Kodumudi, Amod A Sarnaik and Shari Pilon-Thomas state that "treatment with IL PV-10 and anti-PD-1 antibody results in a delay in tumor growth and enhanced T cell activation in the M05 tumor model." They also conclude that "the effect of combination therapy with IL PV-10 and PD-1 blockade is mediated by CD8+ T cells, and depletion of either CD4+ T cells or CD25+ Tregs enhances anti-tumor immunity in the M05 melanoma model." The abstract of the poster (number 4978) may be viewed at: <a href="http://www.abstractsonline.com/4978" title="http://www.abstractsonline.com/4978">http://www.abstractsonline.com/4978</a>. 
Shari Pilon-Thomas, Ph.D., who leads the research team at Moffitt, noted, "Our results show that combining intralesional PV-10 with anti-PD-1 co-inhibitory blockade not only suppresses tumor growth vs. either agent alone but also yields marked increases in tumor-specific T cell activation against injected tumor." 
Eric Wachter, Ph.D., Chief Technology Officer of Provectus, observed, "The nonclinical data reported by our collaborators at Moffitt reaffirm the crucial role T cells play in response to tumor ablation with intralesional PV-10, and further demonstrate the potential value of combining PV-10 with T cell directed checkpoint inhibition, such as the anti-PD-1 agent pembrolizumab. Intriguingly, these data also highlight possible strategies for augmenting this paradigm by harnessing additional targets in T cell signaling." 
Provectus is currently enrolling patients in a phase 3 study of PV-10 as a single agent therapy for patients with locally advanced cutaneous melanoma (Clinical Trials ID NCT02288897) and in a phase 1b study of PV-10 in combination with the immune checkpoint inhibitor pembrolizumab in patients with metastatic melanoma (Clinical Trials ID NCT02557321).

UPDATE: Provectus Says Presentation Showed Treatment with IL PV-10 and Anti-PD-1 Antibody Results in a Delay in Tumor Growth and Enhanced T Cell Activation in the M05 Tumor Model

Provectus Biopharmaceuticals, Inc. (NYSE MKT: <a class="ticker" href="/stock/pvct#NYSE MKT">PVCT</a>) announced today that researchers from Moffitt Cancer Center in Tampa, Florida, presented a poster titled, "T cell Mediated Immunity After Combination Therapy with Intralesional PV-10 and Co-Inhibitory Blockade in a Melanoma Model," at the American Association for Cancer Research (AACR) Annual Meeting 2016, held at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
In the poster, authors Amy M Weber, Hao Liu, Krithika Kodumudi, Amod A Sarnaik and Shari Pilon-Thomas state that "treatment with IL PV-10 and anti-PD-1 antibody results in a delay in tumor growth and enhanced T cell activation in the M05 tumor model." They also conclude that "the effect of combination therapy with IL PV-10 and PD-1 blockade is mediated by CD8+ T cells, and depletion of either CD4+ T cells or CD25+ Tregs enhances anti-tumor immunity in the M05 melanoma model." The abstract of the poster (number 4978) may be viewed at: <a href="http://www.abstractsonline.com/4978" title="http://www.abstractsonline.com/4978">http://www.abstractsonline.com/4978</a>.
Shari Pilon-Thomas, Ph.D., who leads the research team at Moffitt, noted, "Our results show that combining intralesional PV-10 with anti-PD-1 co-inhibitory blockade not only suppresses tumor growth vs. either agent alone but also yields marked increases in tumor-specific T cell activation against injected tumor."
Eric Wachter, Ph.D., Chief Technology Officer of Provectus, observed, "The nonclinical data reported by our collaborators at Moffitt reaffirm the crucial role T cells play in response to tumor ablation with intralesional PV-10, and further demonstrate the potential value of combining PV-10 with T cell directed checkpoint inhibition, such as the anti-PD-1 agent pembrolizumab. Intriguingly, these data also highlight possible strategies for augmenting this paradigm by harnessing additional targets in T cell signaling."
Provectus is currently enrolling patients in a phase 3 study of PV-10 as a single agent therapy for patients with locally advanced cutaneous melanoma (Clinical Trials ID NCT02288897) and in a phase 1b study of PV-10 in combination with the immune checkpoint inhibitor pembrolizumab in patients with metastatic melanoma (Clinical Trials ID NCT02557321).

Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at AACR Annual Meeting 2016

Earnings

Provectus Biopharma Reports Q4 Cash, Cash Equivalents $14.179M vs $17.39M in Same Qtr. Last Year

Provectus Biopharmaceuticals, Inc. (NYSE: <a class="ticker" href="/stock/pvct#NYSE">PVCT</a>) today announced that the protocol for its phase 3 clinical trial for PV-10 as an investigational treatment for melanoma has been amended to reflect current and evolving standards of care and applicable patient population for a global study in melanoma.
Major amendments to the protocol include the addition of talimogene laherparepvec (ImlygicTM) as an option for use as comparator. The amended protocol also extends eligibility to include Stage IV M1a patients having no active nodal or distant cutaneous or subcutaneous metastatic disease. These patients have disease characteristics and prognosis similar to that of the Stage IIIB and IIIC patients that initially defined the study patient population.
In addition, the updated protocol clarifies eligibility for patients not having access to immune checkpoint inhibitors due to standard of care and those not having access to targeted therapy due to standard of care, as well as inclusion of patients who have failed targeted therapy. In the latter case, patients who have failed targeted therapy but meet study eligibility criteria have similar disease manifestations to the remaining study population but have limited treatment options.
Dr. Eric Wachter, CTO of Provectus, said, "These kinds of amendments are commonplace in phase 3 studies and serve to fine-tune the patient population and study procedures to match changing care standards for a large global study. They are the direct result of current and emerging options for these patients and have been developed with extensive input from global leading melanoma investigators. In particular, the most obvious amendment addresses approval in late October of Imlygic by the FDA as the first and only oncolytic viral therapy. As we implement the amended protocol we will assess potential impact on study timelines."

Provectus Biopharmaceuticals Amends Protocol for Phase 3 Study of PV-10 in Treatment of Locally Advanced Cutaneous Melanoma

Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)

Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting

Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders

Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call

Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call

Provectus Biopharmaceuticals Launches VisiRose, Provectus's Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs

Comments

Provectus

Provectus (PVCT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga